On Dec. 12, Biogen said two of its drugs that treat multiple sclerosis, Avonex and Plegridy, will not be discounted through 340B entities’ partner pharmacies. 340B Health President and CEO Maureen Testoni said the decision, which Biogen said will take place Feb. 1, is “depriving safety-net hospitals of needed resources from mandated 340B discounts and keeping those dollars.”
The other pharmaceutical companies that have made similar moves are AbbVie, Amgen, AstraZeneca, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Exelixis, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, UCB and United Therapeutics, according to 340B Health.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.